Confirming this assumption, we observed that necrostatin, an inhibitor of necroptosis, partially rescued the cell viability in crizotinib-treated and BCL2-knockdowned ALK+ ALCL cells, without impairing the autophagic flux (unpublished data). This evidence concerns the gene ALK and anaplastic large cell lymphoma.